Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses ...

The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV specialist ViiV Healthcare in a deal that ...

Novavax (NVAX) shares added ~5% in the premarket on Tuesday after the COVID-19 vaccine maker reached a licensing deal with ...

Novavax ‌said on ‌Tuesday it was ⁠entering ‌into a ‍licensing agreement with ​Pfizer ‌to develop vaccine products ⁠for ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer will relinquish its stake in ViiV Healthcare in a deal valued at just over $2.1 billion that ramps up Shionogi's ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Any believers in UPS who buy now can enjoy a generous dividend payment every quarter while waiting for a turnaround. Given ...